PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Advanced Oncotherapy (AVO)

Advanced Oncotherapy

Two-Year Collaborative Research Study
RNS Number : 5681V
Advanced Oncotherapy PLC
04 December 2019
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

4 December 2019

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Advanced Oncotherapy plc (AIM: AVO) announces a two-year collaborative research study.

 

Under the agreement, Advanced Oncotherapy plc (AIM:AVO) and Cleveland Clinic, a large academic medical centre in Cleveland, Ohio, USA will commence a two-year study to evaluate the target conformity of proton minibeams in comparison with X-ray stereotactic body radiation therapy ("SBRT") and stereotactic radiosurgery ("SRS").

 

Further explanatory details on the research collaboration, SBRT and SRS are set out below.

 

- ENDS -

 

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

Tel: +44 (0) 20 7601 6100



FTI Consulting (Financial PR & IR)

advancedoncotherapy@fticonsulting.com

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About the research collaboration

Innovation in radiotherapy is focused on increasing the efficacy of treatment and improving quality of life for patients through a reduction of side effects or increased long-term survival. The most challenging goal of radiotherapy is ensuring that only the cancerous tissue is targeted, avoiding the irradiation of healthy tissue. The use of a smaller beam means greater accuracy in targeting the desired tissue, which is essential when treating tumours near critical organs, particularly for the edge of the tumours.

 

Focus within proton therapy is on initiatives to generate smaller and more accurate beams. Advanced Oncotherapy's LIGHT has been designed to generate a much smaller beam, a minibeam, than is possible with current proton therapy technology.

 

Proton mini beam radiation therapy ("pMBRT")

Proton minibeam radiation therapy is an approach to radiation therapy that allies the inherent physical advantages of protons with the normal tissue preservation when the tumour is irradiated with sub-millimetric proton beams, i.e., below the current standard size of proton beams.

 

X-ray stereotactic body radiation therapy ("SBRT") and X-ray stereotactic radiosurgery ("SRS")

Stereotactic radiosurgery (SRS) is a non-surgical radiation therapy used to treat functional abnormalities and small tumours of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy. When SRS is used to treat body tumours, it is called stereotactic body radiotherapy (SBRT).

 

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRMMMGZLFNGLZM
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close